PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors

PDS Biotechnology Corporation announced the appointment of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to its Board of Directors effective October 18, 2026. The three executives bring extensive experience in drug development, commercialization, and regulatory affairs. The appointments follow the resignations of four board members. The company is advancing PDS0301 toward Phase 3 trials in metastatic colorectal cancer and pursuing partnerships for PDS0101.